TNFRSF1B +676 T>G polymorphism predicts survival of non-small cell lung cancer patients treated with chemoradiotherapy.
Abstract
The dysregulation of gene expression in the TNF-TNFR superfamily has been involved
in various human cancers including non-small cell lung cancer (NSCLC). Furthermore,
functional polymorphisms in TNF-α and TNFRSF1B genes that alter gene expression are
likely to be associated with risk and clinical outcomes of cancers. However, few reported
studies have investigated the association between potentially functional SNPs in both
TNF-α and TNFRSF1B and prognosis of NSCLC patients treated with chemoradiotherapy.We
genotyped five potentially functional polymorphisms of TNF-α and TNFRSF1B genes [TNF-α
-308 G>A (rs1800629) and -1031 T>C (rs1799964); TNFRSF1B +676 T>G (rs1061622), -1709A>T(rs652625)
and +1663A>G (rs1061624)] in 225 NSCLC patients treated with chemoradiotherapy or
radiotherapy alone. Kaplan-Meier survival analysis, log-rank tests and Cox proportional
hazard models were used to evaluate associations between these variants and NSCLC
overall survival (OS).We found that the TNFRSF1B +676 GG genotype was associated with
a significantly better OS of NSCLC (GG vs. TT: adjusted HR = 0.38, 95% CI = 0.15-0.94;
GG vs. GT/TT: adjusted HR = 0.35, 95% CI = 0.14-0.88). Further stepwise multivariate
Cox regression analysis showed that the TNFRSF1B +676 GG was an independent prognosis
predictor in this NSCLC cohort (GG vs. GT/TT: HR = 0.35, 95% CI = 0.14-0.85), in the
presence of node status (N2-3 vs. N0-1: HR = 1.60, 95% CI = 1.09-2.35) and tumor stage
(T3-4 vs. T0-2: HR = 1.48, 95% CI = 1.08-2.03).Although the exact biological function
for this SNP remains to be explored, our findings suggest a possible role of TNFRSF1B
+676 T>G (rs1061622) in the prognosis of NSCLC. Further large and functional studies
are needed to confirm our findings.
Type
Journal articleSubject
HumansCarcinoma, Non-Small-Cell Lung
Lung Neoplasms
Tumor Necrosis Factor-alpha
Receptors, Tumor Necrosis Factor, Type II
Proportional Hazards Models
Genotype
Polymorphism, Genetic
Aged
Middle Aged
Female
Male
Kaplan-Meier Estimate
Chemoradiotherapy
Permalink
https://hdl.handle.net/10161/18016Published Version (Please cite this version)
10.1186/1471-2407-11-447Publication Info
Guan, Xiaoxiang; Liao, Zhongxin; Ma, Hongxia; Qian, Ji; Liu, Zhensheng; Yuan, Xianglin;
... Wei, Qingyi (2011). TNFRSF1B +676 T>G polymorphism predicts survival of non-small cell lung cancer patients
treated with chemoradiotherapy. BMC cancer, 11(1). pp. 447. 10.1186/1471-2407-11-447. Retrieved from https://hdl.handle.net/10161/18016.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Zhensheng Liu
Assistant Professor of Medicine
Qingyi Wei
Professor in Population Health Sciences
Qingyi Wei, MD, PhD, Professor in the Department of Medicine, is Associate Director
for Cancer Control and Population Sciences, Co-leader of CCPS and Co-leader of Epidemiology
and Population Genomics (Focus Area 1). He is a professor of Medicine and an internationally
recognized epidemiologist focused on the molecular and genetic epidemiology of head
and neck cancers, lung cancer, and melanoma. His research focuses on biomarkers and
genetic determinants for the DNA repair deficient phenotype and
Alphabetical list of authors with Scholars@Duke profiles.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info